# An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

> **NCT02497469** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 771 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Vedolizumab
- **DRUG:** Adalimumab placebo
- **DRUG:** Adalimumab
- **DRUG:** Vedolizumab placebo

## Key facts

- **NCT ID:** NCT02497469
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-29
- **Primary completion:** 2018-09-26
- **Final completion:** 2019-01-18
- **Target enrollment:** 771 (ACTUAL)
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497469, "An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02497469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*